

Pharmacy Policy

Actemra (tocilizumab) Intravenous

Policy Number: 9.156

Version Number: 1.0

Version Effective Date: 1/1/2022

Product Applicability <input type="checkbox"/> All Plan+ Products	
<p>Well Sense Health Plan</p> <input type="checkbox"/> New Hampshire Medicaid	<p>Boston Medical Center HealthNet Plan</p> <input type="checkbox"/> MassHealth - MCO <input type="checkbox"/> MassHealth - ACO <input checked="" type="checkbox"/> Qualified Health Plans/ConnectorCare/Employer Choice Direct <input type="checkbox"/> Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

Prior Authorization Policy

Products Affected:

- Actemra IV

The Plan may authorize coverage of the above products for members meeting the following criteria:

Covered Use	All FDA approved indications not otherwise excluded
Exclusion Criteria	<ol style="list-style-type: none"> 1. Use of Actemra in combination with a biologic DMARD (e.g. Humira, Enbrel, Cimzia, etc.) 2. Use of Actemra in combination with a Janus kinase inhibitor (e.g. Xeljanz)
Required Medical Information	Diagnosis of one of the following: <ol style="list-style-type: none"> 1. Chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS).

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

	<p>2. Moderate to severe Polyarticular juvenile idiopathic arthritis (pJIA) AND</p> <ul style="list-style-type: none"> a. At least five joints with active arthritis AND b. Baseline 10-joint clinical juvenile arthritis disease activity score (cJADAS-10) has been performed; AND a. One of the below: <ul style="list-style-type: none"> i. An inadequate response, or adverse reaction to at least a three month trial of one non-biologic disease modifying anti-rheumatic drug (DMARD) or contraindication to all non-biologic DMARDs; OR ii. Patient will concurrently be starting concurrently with methotrexate, sulfasalazine, or leflunomide; OR iii. Patient has an absolute contraindication to methotrexate, sulfasalazine, or leflunomide; AND b. Patient meets one of the following (i or ii): <ul style="list-style-type: none"> i. An inadequate response, intolerance or contraindication to Simponi Aria; OR ii. According to the prescriber, the patient has heart failure or a previously treated lymphoproliferative disorder. <p>3. Moderate to severe rheumatoid arthritis (RA) (IV and SQ); AND</p> <ul style="list-style-type: none"> a. An inadequate response, or adverse reaction to at least a three month trial of one non-biologic disease modifying anti-rheumatic drug (DMARD) or contraindication to all non-biologic DMARDs; AND b. Patient meets one of the following (i or ii): <ul style="list-style-type: none"> i. Patient tried one of Cimzia or Simponi Aria; OR ii. According to the prescriber, the patient has heart failure or a previously treated lymphoproliferative disorder. <p>4. Systemic juvenile idiopathic arthritis (sJIA); AND</p> <ul style="list-style-type: none"> a. One of the below: <ul style="list-style-type: none"> i. An inadequate response, or adverse reaction to a minimum of a two month trial of one non-biologic DMARD (oral or injectable), or concurrently receiving methotrexate; OR ii. An inadequate response, or adverse reaction to a minimum of a one month trial of one nonsteroidal anti-inflammatory drug; OR iii. An inadequate response, or adverse reaction to a minimum of a two week trial of one glucocorticoid; OR iv. An inadequate response, or adverse reaction to a biologic product approved for systemic juvenile idiopathic arthritis.
Age Restrictions	PJIA, SJIA, CRS: 2 years of age and older RA:18 years of age and older
Prescriber	SJIA, PJIA, RA: Prescribed by or in consultation with a rheumatologist

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Restriction	CRS: Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	Initial and reauthorization: 12 months
Other criteria	Reauthorization: <ol style="list-style-type: none"> 1. Member has met initial criteria. AND 2. Clinical condition has improved or stabilized

Applicable Coding:

Code	Medication
J3262	Actemra® (tocilizumab injection)

Clinical Background Information and References

1. Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; Accessed July 2021.
2. American College of Rheumatology 2008 Recommendations for the use of nonbiologics and biologics disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum.* 2008; 59(6):762-84.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. *Arthritis Rheum.* 2002; 46(2):328-46.
4. Bykerk VP, Ostör AJ, Alvaro-Gracia J et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. *Ann Rheum Dis.* 2012 Dec;71(12):1950-4.
5. De Benedetti F, Brunner HI, Ruperto N et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. *N Engl J Med.* 2012 Dec 20;367(25):2385-95.
6. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicenter, randomized placebo-controlled trial. *Ann Rheum Dis* 2008; 67:1516-23.
7. Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. *J Rheumatol.* 2013 Feb; 40(2):113-26.
8. Food and Drug Administration. FDA approves Actemra to treat rare form of juvenile arthritis. URL: fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251572.htm. Available from Internet. Accessed 2011 April 20. 2324464 3 Pharmacy Medical Necessity Guidelines: Actemra® (tocilizumab)
9. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. *Arthritis Rheum* 2008; 58(10): 2968-80.

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

10. Hunder GG. Treatment of giant cell (temporal) arteritis. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on May 25, 2017).
11. Imagawa T, Yokota S, Mori M et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. *Mod Rheumatol*. 2012 Feb;22(1):109-15.
12. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis; the AMBITION study. *Ann Rheum Dis* 2010; 69:88-96.
13. Kaufmann J, Feist E, Roske AE, Schmidt WA. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. *Clin Rheumatol*. 2013 May 24
14. Nishimoto N, Amano K, Hirabayashi Y et al. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. *Mod Rheumatol*. 2013 May 17.
15. Singh JA, Furst DE, Bharat A et al. Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research*. Vol. 64, No. 5, May 2012, pp 625–639.
16. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2016 Jan;68(1):1-26.
17. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomized trial. *Lancet* 2008; 371:987-97.
18. Strand V, Burmester GR, Ogale S et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. *Rheumatology (Oxford)*. 2012 Oct; 51(10):1860-9.
19. Yazici Y, Curtis JR, Ince A et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. *Ann Rheum Dis*. 2012 Feb; 71(2):198-205.

Original Approval Date	Original Effective Date	Policy Owner	Approved by
8/12/2021	1/1/2022	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

Policy Revisions History			
Review Date	Summary of Revisions	Revision Effective Date	Approved by

* *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Policy Revisions History

8/12/2021	P&T Annual Review: Created two separate policies for IV and SQ formulations; Addition of additional diagnostic criteria and trial requirements for PJIA; Addition of trial requirements and time periods of trial drugs for all indications; Addition of diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and associated clinical criteria and the reauthorization criteria that the member must meet initial criteria.	1/1/2022	P&T Committee
-----------	---	----------	---------------

Next Review Date

8/2022

Other Applicable Policies

Reference to Applicable Laws and Regulations, If Any

Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with

^{*} Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

* *Plan* refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Actemra IV